CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

Autor: Savio Sardinha, Vikas Moudgil, Karl Winckel, Sue Patterson, Terry Stedman, Dan Siskind, Shuichi Suetani, Carmen C.W. Lim, Dylan Flaws, John J. McGrath, Andrea Baker, Anthony W. Russell, Nadia Friend, Steve Kisely

Publikováno v: BMJ Open
Siskind, D, Friend, N, Russell, A, McGrath, J J, Lim, C, Patterson, S, Flaws, D, Stedman, T, Moudgil, V, Sardinha, S, Suetani, S, Kisely, S, Winckel, K & Baker, A 2018, ' CoMET : A protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine ', BMJ Open, vol. 8, no. 3, e021000 . https://doi.org/10.1136/bmjopen-2017-021000

IntroductionClozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ed33e61daf7e5b7c96251780a464a8
https://pubmed.ncbi.nlm.nih.gov/29500217